Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.

Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A, KEYNOTE-966 Investigators

Open source

DOI: 10.1016/s0140-6736(23)00727-4
Published: 2023 Jun 3
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-23-00727-4,
  title = {Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.},
  author = {Kelley RK and Ueno M and Yoo C and Finn RS and Furuse J and Ren Z and Yau T and Klümpen HJ and Chan SL and Ozaka M and Verslype C and Bouattour M and Park JO and Barajas O and Pelzer U and Valle JW and Yu L and Malhotra U and Siegel AB and Edeline J and Vogel A and KEYNOTE-966 Investigators},
  year = {2023},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(23)00727-4},
  url = {https://doi.org/10.1016/s0140-6736(23)00727-4}
}

RIS

TY  - JOUR
TI  - Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
AU  - Kelley RK
AU  - Ueno M
AU  - Yoo C
AU  - Finn RS
AU  - Furuse J
AU  - Ren Z
AU  - Yau T
AU  - Klümpen HJ
AU  - Chan SL
AU  - Ozaka M
AU  - Verslype C
AU  - Bouattour M
AU  - Park JO
AU  - Barajas O
AU  - Pelzer U
AU  - Valle JW
AU  - Yu L
AU  - Malhotra U
AU  - Siegel AB
AU  - Edeline J
AU  - Vogel A
AU  - KEYNOTE-966 Investigators
PY  - 2023
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(23)00727-4
UR  - https://doi.org/10.1016/s0140-6736(23)00727-4
ER  -

APA

RK, K., M, U., C, Y., RS, F., J, F., Z, R., T, Y., HJ, K., SL, C., M, O., C, V., M, B., JO, P., O, B., U, P., JW, V., L, Y., U, M., AB, S., J, E., A, V., & Investigators, K. (2023). Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(23)00727-4

Source records

pubmed · retrieved 2026-09-25T16:29:17.533Z